In April of 2023, Alentis closed the Series C financing round, raising USD 105 million. The funding round was led by Jeito Capital together with Novo Holdings and RA Capital with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.
The financing will support Phase II and Phase I programs of Alentis’ lead investigational products ALE.F02 and ALE.C04 respectively as well as the CLDN1 platform development.
In mid-2021, Alentis closed the Series B financing round, raising USD 67 million. Series B was led by Morningside Venture Investments and Jeito Capital and the Series A investors to accelerate its lead programs for fibrosis and fibrosis-driven cancers into clinical development and to expand the potential of targeting CLDN1 in other fibrotic diseases.
Alentis was founded in 2019 with a CHF 12.5 million Series A financing co-led by Swiss venture capital firms BioMedPartners and BB Pureos Bioventures, with additional investments from Bpifrance, Schroder Adveq, and the German High-Tech Gründerfonds.